Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta‐analysis of randomized controlled trials
Abstract Aims To investigate the renal outcomes of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose transport protein-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus (T2DM) with chronic renal disease (CKD). Materials and Methods PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov were searched through July 2025 for randomized controlled trials […]
Effectiveness and safety of GLP‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
Abstract Aims Acquired hypothalamic obesity (aHO) following craniopharyngioma (CP) is a challenging condition with limited therapeutic options. This study aimed to assess the real-world effectiveness and safety of GLP-1 RAs in this population. Materials and Methods CranioGLP1 is a retrospective multicentre study including 116 adults with aHO treated with one or more GLP-1 RAs across […]
What do Rollerblades and Ozempic have in common?
What do Rollerblades and Ozempic have in common? Host Alex Hogan explains in the latest episode of STATus Report.
Dawn of the weight-loss superpill: They’ll be easier and cheaper to take than jabs. Now ANTONIA HOYLE reveals shock trial results and side-effects every dieter needs to know
The idea was beautifully simple. One pill taken daily to melt away those excess pounds. The new breed of GLP-1 oral medications would be as effective as Mounjaro, but without the need for ‘scary’ injections
Withings’ $380 toilet-mounted urine analyzer is finally ready to buy
It’s been nearly three years since Withings first showed off U-Scan to a bemused world, and now it’s finally on sale. U-Scan is the company’s at-home urinalysis gizmo which sits in your toilet bowl and tests your first splash of the day. The device runs a tiny sample through a microfluidic to test, depending on […]
Eli Lilly’s (LLY) Focus on Innovation and Financial Strength Makes it a Long-Term Winner
Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Rising Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is seen as a strong healthcare stock that investors can confidently hold for many years. Known for its long track record of innovation and extensive drug pipeline, the Indianapolis-based pharmaceutical company boasts impressive […]
Obesity rate is declining as more Americans use weight loss drugs, survey finds – CBS News
Obesity rate is declining as more Americans use weight loss drugs, survey finds CBS News Obesity Rate Declining in U.S. Gallup News Weight loss drugs are bringing down the country’s obesity rate, a survey shows NPR The Needle and the Nation: How Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs are quietly deflating Ame Times of India The obesity rate […]
The Obesity-Drug Revolution Is Stalling
For most of my adult life, I’ve felt helpless about being overweight. When I met with a doctor a few years ago to discuss my high cholesterol, he held up a hunk of faux flesh meant to model a pound of excess fat and encouraged me to lose 20 of said gelatinous blobs. Perhaps, he […]
Lilly keeps up legal fight against GLP-1 compounders
Despite recent setbacks in court, Eli Lilly is doubling down on its fight against compounded weight loss drugs. The pharma giant told Endpoints News on Tuesday that it plans to refile its complaint against the …
Obesity Rate Declining in U.S. (Gallup)
Gallup: Obesity Rate Declining in U.S. — Use of GLP-1 injectables for weight loss has more than doubled since early 2024 — WASHINGTON, D.C. — After peaking at a record high of 39.9% in 2022, the U.S. adult obesity rate has gradually declined to 37.0% in 2025.